Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 28, 2022 07:00 ET | Source: Smart Immune

Smart Immune appoints world-leading experts to its Scientific Advisory Board

Smart Immune appoints world-leading expertsto its Scientific Advisory Board PARIS, France, July 28, 2022 – Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell™, a...
July 06, 2022 07:25 ET | Source: Smart Immune

Marcel R. M. van den Brink, MD, PhD Appointed Chairman of Smart Immune’s Scientific Advisory Board

Marcel R. M. van den Brink, MD, PhD Appointed Chairman of Smart Immune’s Scientific Advisory Board PARIS, France, July 6, 2022 – Smart Immune SAS, a clinical-stage biotechnology...
May 20, 2022 06:00 ET | Source: Smart Immune

Smart Immune Announces Oral Presentation of Cell-Fate Plasticity Data of its T-cell Progenitor-Based Therapy Platform (ProTcell™) at ASGCT 2022

PARIS, May 20, 2022 (GLOBE NEWSWIRE) -- Smart Immune, a clinical-stage biotechnology company focused on saving and improving lives by delivering to patients a new generation of thymus-empowered T...
December 09, 2021 05:30 ET | Source: Smart Immune

Smart Immune Announces Research Collaboration with Memorial Sloan Kettering Cancer Center (MSK) to Expedite Development of a Next Generation CAR-T Through its Long Lasting, Exhaustion-Free CAR ProTcell™ Platform

PARIS, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a clinical stage T-cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus-in-a-dish” technology to develop T-cell...
November 05, 2021 05:30 ET | Source: Smart Immune

Smart Immune Announces Acceptance of Two Abstracts Covering Preclinical Research and Clinical Data at the American Society of Hematology

PARIS, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a T-cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus in a dish” technology to develop allogeneic T-cell...
October 13, 2021 07:00 ET | Source: Smart Immune

Smart Immune Receives IRB Approval For Phase 1/2 Clinical Trial of Proprietary Allogeneic T-cell Product Smart-101 (ProTcell™) for AML and ALL

PARIS, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a T cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus in a dish” technology to develop allogeneic T-cell...
September 29, 2021 09:00 ET | Source: Smart Immune

TNFα-supplemented DL-4 culture system supports first-in-clinic Smart Immune ProTcell™ technology for immuno-deficient patients fighting cancers and infections

PARIS, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS’s unique ex-vivo biomimetic ProTcell™ ‘thymus in a dish’ platform technology, designed to generate specific human T-cell progenitor cells...
May 10, 2021 05:30 ET | Source: Smart Immune

Smart Immune Announces FDA Orphan Drug Status, IND Acceptance and Fast-Track Designation to Commence Phase 1/2 Clinical Trial of Proprietary Allogeneic T cell Progenitor Product SMART 101 (ProTcell™) for AML and ALL

PARIS, May 10, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a T cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus in a dish” technology to develop proprietary allogeneic T...

keyboard_arrow_left Previous Page